Medline Inc

Medline Inc(MDLN)股票分析

$36.590

+0.293 (+0.80%)收盘时

Loading chart…
High
36.930
Open
36.520
VWAP
36.36
Vol
5.83M
Mkt Cap
Low
35.550
Amount
211.85M
EV/EBITDA, TTM
62.39

Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.

AI analysis of Medline Inc (MDLN)

buy

Medline Inc. is a good buy right now due to its recent strong earnings performance, with a reported EPS of $0.50, beating expectations by $0.18, and a revenue of $7.7 billion for Q2, reflecting an 11.6% year-over-year growth. However, the risk lies in the lowered EBITDA outlook, now projected between $3.3 billion to $3.4 billion, which is below market expectations.

估值指标

The current forward P/E ratio for Medline Inc (MDLN) is 21.41, compared to its 5-year average forward P/E of 32.56.

Forward P/E

Fair
5Y Average P/E
32.56
Current P/E
21.41
高估
46.50
低估
18.62

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
23.24
Current EV/EBITDA
62.39
高估
34.25
低估
12.24

Forward P/S

Fair
5Y Average P/S
1.47
Current P/S
1.45
高估
2.00
低估
0.93

Whales holding MDLN

R

Readystate Asset Management LP

+ HoldingMDLN

+17.13%

3M Return

A

Abu Dhabi Investment Authority

+ HoldingMDLN

+6.15%

3M Return

H

Healthcare of Ontario Pension Plan Trust Fund

+ HoldingMDLN

+5.55%

3M Return

A

Alyeska Investment Group, L.P.

+ HoldingMDLN

+4.89%

3M Return

E

Egerton Capital (UK) LLP

+ HoldingMDLN

+4.67%

3M Return

B

BW Gestao de Investimentos Ltda.

+ HoldingMDLN

+4.40%

3M Return

事件时间线

2026-08-05 (ET)

08:30:00

Company Raises 2026 Organic Sales Growth Outlook to 9.0%-10.0%

08:30:00

Medline Reports Q2 Revenue of $7.69B

2026-07-08 (ET)

11:30:00

Medline Signs New Prime Vendor Agreement with Allina Health

2026-07-06 (ET)

12:00:00

Medline Signs New Warehouse Lease in California, Expands 45%

2026-06-12 (ET)

10:30:00

William Blair Analyst Says Medline Shares Drop Due to California Fire

资讯

MDLN FAQ — answered by Alphio AI

Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers. It operates in the Healthcare sector.

Medline Inc. is a good buy right now due to its recent strong earnings performance, with a reported EPS of $0.50, beating expectations by $0.18, and a revenue of $7.7 billion for Q2, reflecting an 11.6% year-over-year growth. However, the risk lies in the lowered EBITDA outlook, now projected between $3.3 billion to $3.4 billion, which is below market expectations.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始